{"id":46254,"date":"2014-01-13T20:04:56","date_gmt":"2014-01-14T01:04:56","guid":{"rendered":"http:\/\/countingpips.com\/forex-news\/?p=46254"},"modified":"2014-01-13T20:04:56","modified_gmt":"2014-01-14T01:04:56","slug":"a-biotech-bubble-or-biotech-catch-up","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/forex-news\/2014\/01\/13\/a-biotech-bubble-or-biotech-catch-up\/","title":{"rendered":"A Biotech Bubble or Biotech Catch-up?"},"content":{"rendered":"<p>By <a href=\"http:\/\/www.MoneyMorning.com.au\" target=\"_blank\"><u>MoneyMorning.com.au<\/u><\/a><\/p>\n<p>My colleagues and I are a little worried about overvaluation of a lot of  <strong>biotech stocks<\/strong>, especially some of the new initial public offerings this year. <\/p>\n<p>Those who warn of a <strong>biotech bubble <\/strong>are correct to think that a lot of  biotech stocks seem to keep going up without any good reason. Despite mightily  thin pipelines and drugs still stuck in Phase 2 trials, a lot of biotechs seem  to have climbed on pure hope. But my experience with biotech stocks is that  it&#8217;s not wise to think of them as a group. As is true with most things,  generalizations don&#8217;t offer good information &#8211; specifics do. <\/p>\n<p>So yes, this was a banner year for IPOs of biotech companies &#8211; at least  34 of them, at last count. But frankly, I wish it had been more of a blowout  and that the blowout had started five years ago. Biotechs have been depressed  for a decade. The truth is that there are hundreds of small startup companies  that have great ideas, great products and great futures &#8211; but they haven&#8217;t gone  public. In many cases, the reason is purposeful &#8211; so they won&#8217;t get gobbled up  by a Big Pharma company before they&#8217;ve had a chance to show what they can do. <\/p>\n<p>Many of the researchers and scientists developing new drugs and  procedures and instruments are immensely proud of their accomplishments and  have a passion to prove their ideas are correct. They don&#8217;t want to lose  control of their direction and their work. <\/p>\n<p>Examples abound of companies with great drugs that went public too soon  and got eaten by a pharma giant. Then the originators watched helplessly as  their drug &#8211; which actually worked and was sailing through to Food and Drug  Administration approval &#8211; was canned by marketing pros and bean counters who  decided the return on investment just wasn&#8217;t good enough. Big companies think  very differently from startups.<strong> <\/strong><\/p>\n<h2>Biotech  IPOs: Don&#8217;t Lose Sight of These Two Takeaways<\/h2>\n<\/p>\n<p>What&#8217;s lost in the hubbub about all these new IPOs soaring are two  things. <\/p>\n<p>First, a lot of them have gone down in value, not up. <\/p>\n<p>Second, and more importantly, the surge of IPOs now only reflects the  dearth of biotech IPOs in the last 10 years. It has been a desert out there for  investors in this critical field. And 35 or so IPOs in one year for biotechs  may seem like a lot, but averaged out over the last 10 years, it&#8217;s nothing.  Predictions are for another 35-40 to go public in 2014.<\/p>\n<p>Having said all that, I too am worried about a January-April sell-off in  2014 of the overall market. And we all know that stocks floating on hope get  hit the hardest in downturns. <\/p>\n<p>If there&#8217;s a market downturn, almost all biotech stocks will drop for  the time being. But that may also represent another buying opportunity, and  that reminds me of one of Warren Buffett&#8217;s most famous speeches, supposedly  given during a talk at Columbia University when he was 21: <\/p>\n<blockquote>\n<p>&#8216;<em>A  simple rule dictates my buying: Be fearful when others are greedy, and be  greedy when others are fearful&#8230; Let me be clear on one point: I can&#8217;t predict  the short-term movements of the stock market. I haven&#8217;t the faintest idea as to  whether stocks will be higher or lower a month or a year from now. What is  likely, however, is that the market will move higher, perhaps substantially so,  well before either sentiment or the economy turns up. So if you wait for the  robins, spring will be over.<\/em>&#8216; <\/p>\n<\/blockquote>\n<p>Even in a severe downturn, <a rel=\"nofollow\" href=\"http:\/\/pro1.portphillippublishing.com.au\/179324\/\" target=\"_blank\">specific biotech stocks<\/a> can  move dramatically upward, because success in this area depends on success in  trials research and FDA decisions. <\/p>\n<p>Regards,<\/p>\n<p>Stephen Petranek<br \/>\nContributing Editor, <em>Money Morning<\/em> <\/p>\n<\/p>\n<p><strong><a href=\"https:\/\/plus.google.com\/106516983215198267222\/about\" title=\"Join Money Morning on Google Plus -- and read about the things we can't always fit into our regular essays\"><u>Join Money Morning on Google+ <\/u><\/a><\/strong><\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/MoneyMorningAustralia?a=sXjKeo4gzwc:35YIi850Xvw:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/MoneyMorningAustralia?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/MoneyMorningAustralia?a=sXjKeo4gzwc:35YIi850Xvw:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/MoneyMorningAustralia?i=sXjKeo4gzwc:35YIi850Xvw:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/MoneyMorningAustralia?a=sXjKeo4gzwc:35YIi850Xvw:gIN9vFwOqvQ\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/MoneyMorningAustralia?i=sXjKeo4gzwc:35YIi850Xvw:gIN9vFwOqvQ\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/MoneyMorningAustralia\/~4\/sXjKeo4gzwc\" height=\"1\" width=\"1\" \/><br \/>\nBy <a href=\"http:\/\/www.MoneyMorning.com.au\" target=\"_blank\"><u>MoneyMorning.com.au<\/u><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By MoneyMorning.com.au My colleagues and I are a little worried about overvaluation of a lot of biotech stocks, especially some of the new initial public offerings this year. Those who warn of a biotech bubble are correct to think that a lot of biotech stocks seem to keep going up without any good reason. Despite &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.investmacro.com\/forex-news\/2014\/01\/13\/a-biotech-bubble-or-biotech-catch-up\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;A Biotech Bubble or Biotech Catch-up?&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-46254","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/posts\/46254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/comments?post=46254"}],"version-history":[{"count":0,"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/posts\/46254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/media?parent=46254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/categories?post=46254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/forex-news\/wp-json\/wp\/v2\/tags?post=46254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}